Science Current Events | Science News | Brightsurf.com
 

Rejected Alzheimer's drug shows new potential

July 31, 2012
Study suggests that latrepirdine, which previously failed in clinical trials, may be successful if tested on patients with earlier stages of the disease

An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease. The findings, published July 31, 2012 in Molecular Psychiatry, demonstrate renewed potential for this compound and could lead to clinical trials in patients with early stages of the disease.

Latrepirdine, known commercially as Dimebon, was initially sold as an antihistamine in Russia, approved for use there in 1983. In the 1990s, researchers at the Institute of Physiologically Active Compounds in Moscow determined that the compound appeared effective in treating Alzheimer's disease in animals. They continued their research in humans and performed several studies, including Phase I and II trials, all of which showed significant and sustained improvement in cognitive behavior with minimal side effects. The Phase II trials, performed in Russia, were overseen by U.S. Alzheimer's researchers, including Mary Sano, PhD, Director of the Mount Sinai Alzheimer's Disease Research Center.

However, when research was continued in the United States in a Phase III trial, the drug did not demonstrate any improvement in people with the disease, causing the sponsors to halt further clinical study of the drug in Alzheimer's disease. Some researchers have speculated that the Russian patients might have had different disease stage or subtype of Alzheimer's, and therefore were more responsive to treatment than the patients in the Phase III trials in the United States.

Before the failed trials were announced, researchers at Mount Sinai School of Medicine, led by Sam Gandy, MD, PhD, Professor of Neurology, and Psychiatry, and Director of the Mount Sinai Center for Cognitive Health, began studying the mechanism of action behind latrepirdine in the current study, which is supported by the Cure Alzheimer's Fund.

Dr. Gandy's team randomly administered either latrepirdine or placebo to mice engineered to present the early stages of Alzheimer's disease and found that the drug halted both behavioral decline and progression of neuropathology. In evaluating how latrepirdine improved memory, John Steele, PhD, a neuroscience graduate student working with Dr. Gandy, and Lenard Lachenmayer, MD, a postdoctoral fellow working under the supervision of Zhenyu Yue, PhD, Associate Professor of Neurology at Mount Sinai, found that the drug enhanced autophagy, the so-called "self-eating" process of cells that protects the brain from neurodegeneration.

"When we learned that latrepirdine failed in patients in the United States in 2010, scientists around the world were disappointed and perplexed," Dr. Gandy said. "We wanted to find out why the drug did so well in Russia but then showed no effect in the global studies. The findings from our animal model studies indicated that this drug should not be discarded, and that, if its mechanism of action can be optimized, it still has potential."

Dr. Sano points out that not only did latrepirdene have significant and sustained effect in the Russian study but it also showed a mild effect in one study of patients with Huntington's disease.

"Since cognitive benefit is what really matters to patients and families, it is critical that we explore every mechanism by which it might occur," Dr. Sano said.

"While this is just the beginning, our research shows that this previously cast-off drug still has strong therapeutic promise," Dr. Gandy said. "Autophagy drugs are believed to hold great promise for a range of neurodegenerative diseases, and these data raise the question of whether further basic science work on latrepirdine might lead to optimization of the drug so that a more potent drug could be developed, and subsequently tested in human clinical trials.

"This is especially true since we know that latrepirdine is an extremely safe drug and in view of the recent failure of the first key trial of the drug bapineuzumab," Dr. Gandy added. "Also, as may be the case with all amyloid-lowering drugs, initiating latrepirdine trials before amyloid deposition begins may be the key. Now, with the new brain amyloid scans that began at Mount Sinai in June, we can easily establish who those patients are."

Looking ahead, Drs. Gandy, Yue, and their collaborators are planning to test latrepirdine in mouse models of other protein buildup diseases such as Parkinson's disease, Lewy body dementia, and chronic traumatic encephalopathy, the Alzheimer's-like condition athletes endure from boxing, football and hockey. Dr. Sano notes that so few agents show any improvement in cognition that it is critical that to exhaust every potential lead.

Mount Sinai has a long-standing legacy of critical breakthroughs in team research in Alzheimer's disease. Dr. Gandy is an internationally-renowned expert in understanding the amyloid plaques characteristic of Alzheimer's disease, and he led a team of researchers to the discovery of the first drugs that reduced amyloid buildup. Dr. Sano is a world leader in designing clinical trials to find treatments and preventions for cognitive loss and Alzheimer's disease. Together, their labs and the Mount Sinai Alzheimer's Disease Research Center and Center for Cognitive Health are focused on a strategic approach to translating clinical challenges into bench investigations and back.

The Mount Sinai Hospital / Mount Sinai School of Medicine


Related Alzheimer's Disease Current Events and Alzheimer's Disease News Articles


Cracking the code of brain development
With a unique, multi-faceted approach, researchers at the Lieber Institute for Brain Development (LIBD) have quantified the effect of previously unidentified anomalies in genetic expression that determine how the human brain develops from its earliest stages.

Study: Novel agent decreases neuropathic pain in patients with type 2 diabetes
Molecular Medicine, a peer-reviewed biomedical journal published by the Feinstein Institute Press, published the results of a new study reporting clinically significant pain reduction in type 2 diabetic patients.

Signaling mechanism could be target for survival, growth of tumor cells in brain cancer
UT Southwestern Medical Center neurology researchers have identified an important cell signaling mechanism that plays an important role in brain cancer and may provide a new therapeutic target.

Early identification of modifiable risk factors for cognitive decline
Signs of cognitive decline related to aging populations, and even the severe cognitive losses seen in Alzheimer's disease and neurodegenerative disorders, may emerge many years earlier, according to a report presented today at the American College of Neuropsychopharmacology annual meeting in Phoenix (Arizona).

Peroxisome proliferator-activated receptor agonists may treat alcohol dependence
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptor proteins that regulate the expression of genes. Drugs that activate PPARs - PPAR agonists - are used to treat diabetes and elevated blood lipids.

Can poor sleep lead to dementia?
People who have sleep apnea or spend less time in deep sleep may be more likely to have changes in the brain that are associated with dementia.

Sleep disturbance linked to amyloid in brain areas affected by Alzheimer's disease
Healthy, elderly research participants who report being more sleepy and less rested have higher levels of amyloid deposition in regions of the brain that are affected in Alzheimer's disease, according to a report presented today at the American College of Neuropsychopharmacology annual meeting in Phoenix (Arizona).

Even the perceived risk of disease prompts intention to actEven the perceived risk of disease prompts intention to act
With so much focus on risk factors for disease, we are living in an era of surveillance medicine, in which the emphasis on risk blurs the lines between health and illness, argue researchers at Yale and Syracuse universities in a study published in the December issue of the Journal of Health and Social Behavior.

Researchers at Mainz University explore new approach for treating Alzheimer's disease
It is estimated that about 35 million people worldwide currently suffer from dementia and it is expected that the number will increase to 135 million by the year 2050.

'Alzheimer's in a Dish' model induces skin cells into neurons expressing amyloid-beta
The search for a living laboratory model of human neurons in the grip of Alzheimer's disease (AD)--the so-called "Alzheimer's in a dish"--has a new candidate.
More Alzheimer's Disease Current Events and Alzheimer's Disease News Articles

The Alzheimer's Diet: A Step-by-Step Nutritional Approach for Memory Loss Prevention and Treatment (Volume 1)

The Alzheimer's Diet: A Step-by-Step Nutritional Approach for Memory Loss Prevention and Treatment (Volume 1)
by Richard S Isaacson MD (Author), Christopher N Ochner PhD (Author)


Harvard-trained Neurologist, Dr. Richard Isaacson and renowned nutrition expert, Dr. Christopher Ochner team up to create this ground-breaking nutritional guide for individuals concerned about memory loss. In recent years, there has been an explosion in research on nutritional interventions for Alzheimer’s prevention and treatment, which is considered to be the most severe public health crisis of our day. These specific dietary interventions present new hope for individuals concerned about memory loss, and also have rapidly expanding scientific-evidence to support their effectiveness. Based on empirical evidence, The Alzheimer’s Diet outlines what to eat, what not to eat, and highlights a step-by-step approach for improving memory and protecting the brain through diet. This...

Alzheimer's Disease: What If There Was a Cure?

Alzheimer's Disease: What If There Was a Cure?
by Mary T. Newport (Author)


The first edition of Alzheimer's Disease: What if There Was a Cure?, which details Dr. Newport's discovery and use of medium-chain fatty acids (which act like alternative fuel in the Alzheimer's brain), had such a strong reception in 2011 that a second edition is now in demand. In this updated and expanded version, Dr. Newport, a neonatal practitioner, continues the story of her husband Steve's progress and provides the most recent research on the possible connection between Alzheimer's disease and the herpes simplex virus and nitrosamine substances, as well as how infection, inflammation, and genetic makeup may affect an individual's response to fatty acid therapy. Among many other updates, Dr. Newport details the latest clinicaltrials aimed at removing beta-amyloid, which accumulates in...

Alzheimer's Disease: What If There Was a Cure?

Alzheimer's Disease: What If There Was a Cure?
by Mary T. Newport (Author), Cheryl Hirsch (Editor)


Though Dr. Mary T. Newport has provided professional care to newborns since 1983, she's led a double life since 2000 when she became a caregiver at home. That's when her beloved husband, Steve, first showed signs of Alzheimer's disease. After his deterioration accelerated in 2004, Dr. Newport began avidly researching ways to keep him functional for as long as possible. Since she understands medical terminology and scientific methods, she was thrilled to find new research showing that medium- chain fatty acids, which act like an alternative fuel in the insulin-deficient Alzheimer's brain, can sometimes reverse or at least stabilize the disease. When she gave Steve about 2 tablespoons of coconut oil (a source of these fats) at breakfast before a memory test that he had previously failed,...

Second Forgetting: Remembering the Power of the Gospel during Alzheimer's Disease

Second Forgetting: Remembering the Power of the Gospel during Alzheimer's Disease
by Dr. Benjamin T. Mast (Author), Scotty Smith (Foreword)


Charles is 78 years old and there is much he cannot remember. He cannot remember the names of his children, why he lives in a nursing home, or even whether he ate breakfast today. His forgetting causes confusion, and in his fear and uncertainty he sometimes lashes out at those who try to care for him. But when someone reads a favorite Psalm he quickly joins in, reciting each cherished word. When he hears an old hymn of faith, his hand slowly raises and he breathes out each word quietly, his face reflecting a peace that passes all understanding. Alzheimer’s disease has been described as the “defining disease” of the baby boomer generation. Millions of Americans will spend much of their retirement years either caring for a loved one with Alzheimer’s disease or experiencing its...

Alzheimer's Treatment Alzheimer's Prevention: A Patient and Family Guide, 2012 Edition

Alzheimer's Treatment Alzheimer's Prevention: A Patient and Family Guide, 2012 Edition
by Dr. Richard S Isaacson MD (Author)


Harvard-trained Neurologist Dr. Richard Isaacson answers the most common patient and caregiver questions on the treatment and prevention of Alzheimer's disease (AD). He shares his cutting edge, comprehensive approach in the fight against AD, the greatest public health crisis today. This groundbreaking book has been written especially for patients, caregivers, family members, and allied healthcare professionals. Dr. Isaacson writes in easy to understand terms and easy to read (larger-type) print to help educate and inform those confronting AD. He outlines his comprehensive and scientifically-based approach that includes a comprehenisve 9-week diet and nutrition plan, with examples of what to eat, what not to eat, and a food terminology guide to help read and understand nutrition labels. ...

Alzheimer's Disease: Alzheimer's Stage By Stage, The Alzheimer's Diet And Alzheimer's Caregivers Guide (Alzheimer's Disease, Dementia Help Book 1)

Alzheimer's Disease: Alzheimer's Stage By Stage, The Alzheimer's Diet And Alzheimer's Caregivers Guide (Alzheimer's Disease, Dementia Help Book 1)


Get The Information You NEED To Deal With Alzheimer’s Disease Right Away!
Today only, get this Kindle book for just $2.99. Regularly priced at $5.99. Read on your PC, Mac, smart phone, tablet or Kindle device.

Have you or a loved one been diagnosed with Alzheimer's disease? Are you unsure of what to expect? Things may seem okay today, but Alzheimer's disease eventually will rob you or your loved one of all of the cherished memories and recognition capabilities. How do you know if you are suffering from Alzheimer's disease?

Age-related memory problems and the beginning stages of Alzheimer's disease can look remarkably the same. Download this book NOW and:
Learn What The Signs And Symptoms Of Alzheimer's Disease Are. Learn The Difference Between...

A Caregiver's Guide to Alzheimer's Disease: 300 Tips for Making Life Easier

A Caregiver's Guide to Alzheimer's Disease: 300 Tips for Making Life Easier
by Patricia R. Callone (Author), Connie Kudlacek (Author), Barabara C. Vasiloff (Author), Janaan Manternach (Author), Roger A. Brumback (Author)


An estimated 5 million Americans have Alzheimer's disease. That number continues to grow - by 2050 the number of individuals with Alzheimer's could range from 11.3 million to 16 million. Alzheimer's disease is not a normal part of aging. It is a devastating disorder of the brain's nerve cells that impairs memory, thinking, and behavior. Written for patients, their families, and caregivers, A Caregiver's Guide to Alzheimer's Disease: 300 Tips for Making Life Easier will help readers understand what is physically happening to the brain so they can empower their own special skills and talents throughout the disease process. The book is divided into three sections that correspond to the progression of Alzheimer's and the unique challenges encountered at each stage.Section A: The major part of...

Where Two Worlds Touch: A Spiritual Journey Through Alzheimer's Disease

Where Two Worlds Touch: A Spiritual Journey Through Alzheimer's Disease
by Jade C. Angelica (Author)


Jade Angelica shares the wisdom and hope she gleaned from caring for her mother and from many years working closely with Alzheimer's patients and caregivers. Challenging the predominant belief that people with Alzheimer's no longer have purpose, potential, or the capacity for meaningful relationship, Where Two Worlds Touch is both a spiritual memoir and a pastoral guide for those who love someone with Alzheimer's. Readers will find here the reassuring words of a friend who has been there and can give advice on preserving connection, finding hope, self-care, and staying open to the possibility of grace.

The 36-Hour Day: A Family Guide to Caring for People Who Have Alzheimer Disease, Related Dementias, and Memory Loss

The 36-Hour Day: A Family Guide to Caring for People Who Have Alzheimer Disease, Related Dementias, and Memory Loss
by Nancy L. Mace (Author), Peter V. Rabins (Author)


When someone in your family suffers from Alzheimer disease or other related memory loss diseases, both you and your loved one face immense challenges. For over thirty years, this book has been the trusted bible for families affected by dementia disorders. Now completely revised and updated, this guide features the latest information on the causes of dementia, managing the early stages of dementia, the prevention of dementia, and finding appropriate living arrangements for the person who has dementia when home care is no longer an option.

You'll learn:
-The basic facts about dementia
-How to deal with problems arising in daily care-- meals, exercise, personal hygiene, and safety
-How to cope with an impaired person's false ideas, suspicion, anger, and other mood...

The 36-Hour Day: A Family Guide to Caring for People with Alzheimer Disease, Other Dementias, and Memory Loss in Later Life, 4th

The 36-Hour Day: A Family Guide to Caring for People with Alzheimer Disease, Other Dementias, and Memory Loss in Later Life, 4th
by Nancy L. Mace (Author), Peter V. Rabins (Author)


Revised in 2006 for its twenty-fifth anniversary, this best-selling book is the "bible" for families caring for people with Alzheimer disease, offering comfort and support to millions worldwide. In addition to the practical and compassionate guidance that have made The 36-Hour Day invaluable to caregivers, the fourth edition is the only edition currently available that includes new information on medical research and the delivery of care. The new edition includes: - new information on diagnostic evaluation
- resources for families and adult children who care for people with dementia
- updated legal and financial information
- the latest information on nursing homes and other communal living arrangements
- new information on research, medications, and the biological...

© 2014 BrightSurf.com